23 results
424B3
ADAP
Adaptimmune Therapeutics Plc
20 Apr 23
Prospectus supplement
4:32pm
funding, general economic conditions including those resulting from the COVID-19 pandemic, macro-economic climate and the war in Ukraine, trends
S-4/A
ADAP
Adaptimmune Therapeutics Plc
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
, general economic conditions including those resulting from the COVID-19 pandemic, macro-economic climate and the war in Ukraine, trends
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
11 Apr 23
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
8:08am
, pandemic (including unforeseen effects of the COVID-19 pandemic, and any recurrence or worsening thereof), act of government or governmental agency
S-4
ADAP
Adaptimmune Therapeutics Plc
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
pandemic, macro-economic climate and the war in Ukraine, trends in the biotechnology industry, regulatory and financial market conditions and other
8-K
EX-99.1
dcr oh6yrbb25uwvuiwt
25 Feb 21
Adaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business Update
7:37am
S-3ASR
pd65v
10 Aug 20
Automatic shelf registration
5:01pm
8-K
EX-99.1
2o9e2es c98en42
6 Aug 20
Adaptimmune Reports Q2 Financial Results and Business Update
7:37am
424B5
f3y4yynep3aok8glu
2 Jun 20
Prospectus supplement for primary offering
5:05pm
424B5
f2kbblvv8elqg
1 Jun 20
Prospectus supplement for primary offering
6:06am